Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 8/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.44 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.44 |
| ▸ | ITGAL | P20701 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8239577 | 0.86 | FEN1 (0.57) | MEN1KMT2AMAPTJAK2JAK1 | |
| SCHEMBL1162543 | 0.86 | CES2 (0.56) | MEN1KMT2ACES2CES1MAPT | |
| SCHEMBL3467976 | 0.81 | KMT2A (0.56) | MEN1KMT2AGAACES2CES1 | |
| SCHEMBL30016040 | 0.81 | KMT2A (0.56) | MEN1KMT2AGAACES2CES1 | |
| SCHEMBL2070130 | 0.80 | MEN1 (0.58) | MEN1KMT2AGAAMAPTRAB9A | |
| SCHEMBL24451122 | 0.79 | CA9 (0.48) | MEN1KMT2AMAPTJAK2JAK1 | |
| SCHEMBL12780415 | 0.79 | CA9 (0.48) | MEN1KMT2ACES2CES1MAPT | |
| SCHEMBL14454136 | 0.79 | CES2 (0.48) | MEN1KMT2ACES2CES1RAB9A | |
| SCHEMBL13181078 | 0.79 | CES2 (0.48) | MEN1KMT2AGAACES2CES1 | |
| SCHEMBL9720600 | 0.79 | TYK2 (0.47) | MEN1KMT2AJAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023183394-A1 | ALPHA 1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | CURASEN THERAPEUTICS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2015005901-A1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-15 | — | — | WO | disclosed |
| WO-2013106520-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | WO | disclosed |
| WO-2012065062-A1 | NOVEL ANTIVIRAL COMPOUNDS | PHARMARESOURCES(SHANGHAI)CO., LTD. (CN) | 2012-05-18 | — | — | WO | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090192138-A1 | COMPOUNDS | BAESCHLIN DANIEL KASPAR | 2009-07-30 | — | — | US | disclosed |
| US-20090192138-A1 | COMPOUNDS | BAESCHLIN DANIEL KASPAR | 2009-07-30 | — | — | US | disclosed |
| WO-2007071738-A1 | CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192138-A1 | COMPOUNDS | DPP4, DPP3, DPP8 | MEN1 2523/4885KMT2A 2541/4885GAA 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.